Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer: The IMPROVE TrialAntonio Avallone, Alfredo Budillon, Francesco Giuliani et al.|Journal of Clinical Oncology|2024Cited by 14
Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy EfficacyGerardo Rosati, Antonio Avallone, Giuseppe Aprile et al.|Biomedicines|2022Cited by 14
Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT studyGerardo Rosati, Domenico Bilancia, Giuseppe Aprile et al.|Journal of Geriatric Oncology|2021Cited by 5
An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal CancerGerardo Rosati, Domenico Bilancia, Michele Montrone et al.|Journal of Clinical Medicine|2022Cited by 2
RAS/BRAF testing of circulating cell-free DNA (cfDNA) in RAS/BRAF wild-type (RAS/BRAF <sup>WT</sup> ) metastatic colorectal cancer (mCRC) patients: Preliminary results of the phase III LIBImAb study.Anna Maria Rachiglio, Carmine Pinto, Angela Damato et al.|Journal of Clinical Oncology|2025Cited by 1